Pretty much bang on. This is as expected (well, for me, for the most part) and, if you're an interested holder, back to watching CC and medical devices divisions. Its clear that this has been a primary target for the past few months.
I would like for us to get some decisive action going forward on immunotherapies while concentrating on growing CC and medical devices. The HSV2 program has been a distraction for so long that it is time to pack it away.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-63
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |